Diamedica Therapeutics Inc DMAC

$8.25 +0.23 (2.87%)

Valuation

Market cap
432,735,000
Revenue TTM
$0
Net income TTM
$-32,770,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
313,500
Avg volume
230,974
Day's range
$7.88 – $8.39
Shares out
53,957,000
Stochastic %K
19%
Beta
0.95
Analysts
Strong Buy
Price target
$15.50

Price

Company profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal g...

Show more

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Industry
Biotechnology
Sector
Healthcare
Phone
763 496 5454
Website
https://www.diamedica.com
Address
301 Carlson Parkway, Suite 210, Minneapolis, United States

Latest news

Stocktwits

Danger_Will_Robinson Nov 20, 8:44 PM
$DMAC some green im a sea of red …. I’ll take it!
0 replies
YouVSYou Nov 20, 1:23 PM
Tuesday look ahead events $DMAC ($8.02) First on my list Phase 2 data at 8am ET. Only 12 patients Need a clean safety read and enough of a signal to move the study forward $CLSK ($5.84) Earnings after close We know the $6.6B data center lease is signed When does the site go live and when does rent start? That’s what I’m listening for $RIG ($4.77) Valaris vote. $200M+ in annual savings if the deal closes If both sides say yes, give me a real closing timeline before I chase a candle
0 replies
Stock_picker_trader Nov 16, 11:58 PM
$DMAC Leon Cooperman is still in and hasn’t sold a single share
0 replies
Relee187200 Nov 13, 2:46 PM
$DMAC Sucks.
1 replies
Relee187200 Nov 13, 2:33 PM
$DMAC Damn.
0 replies
Merlintrader Nov 13, 1:44 PM
$DMAC DiaMedica, Nov 12: Q3 results with 34.9 million dollars of liquidity at Sept 30. ReMEDy2 passed 200 enrolled patients, with an interim in Q1 2027, and preliminary FGR findings are scheduled for Nov 24. Not investment advice. Read more in the $DMAC stock hub: https://www.merlintrader.com/diamedica-therapeutics-stock-hub/
0 replies
StocktwitsEarnings Nov 13, 11:00 AM
$DMAC Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.21 down -23.53% YoY • DiaMedica expects quarterly expenses and negative operating cash flows to increase moderately relative to recent prior periods as clinical development advances, including ReMEDy2 and the Phase 2 PE trial.
0 replies
Relee187200 Nov 11, 8:58 PM
$DMAC Weak
0 replies